Emergence and Persistence of Minor Drug-Resistant HIV-1 Variants in Ugandan Women after Nevirapine Prophylaxis
Author Information
Author(s): Andrea Hauser, Kizito Mugenyi, Rose Kabasinguzi, Claudia Kuecherer, Gundel Harms, Andreas Kunz
Primary Institution: Institute of Tropical Medicine and International Health, Charité – Universitätsmedizin Berlin
Hypothesis
How do drug-resistant HIV-1 variants emerge and persist in Ugandan women after nevirapine single-dose prophylaxis?
Conclusion
The study found that a one-week medication may be insufficient to prevent the emergence of nevirapine resistance in many women.
Supporting Evidence
- 62% of women developed NVP-resistant virus during the observation period.
- Resistance rates increased from 18% at week 1 to 44% at week 6 before declining.
- The maximum proportion of NVP-resistant HIV-1 was significantly higher in subtype D than subtype A.
Takeaway
This study looked at how some women developed drug-resistant HIV after taking a medicine to prevent passing the virus to their babies, showing that the medicine might not work as well as hoped.
Methodology
The study used allele-specific PCR assays to measure drug-resistant HIV-1 variants in blood samples taken from women at various time points after nevirapine prophylaxis.
Potential Biases
Potential bias due to the study being conducted in a specific geographic area with a limited demographic.
Limitations
The small sample size may limit the generalizability of the findings.
Participant Demographics
The participants were HIV-1 positive pregnant women from Uganda, with a median age of 25 years.
Statistical Information
P-Value
p=0.032
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website